<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> is associated with abdominal <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Adiponectin is a <z:chebi fb="7" ids="16670">peptide</z:chebi> that is secreted from adipocytes and circulates in three multimeric forms: low molecular weight (LMW), middle molecular weight (MMW), and high molecular weight (HMW) </plain></SENT>
<SENT sid="2" pm="."><plain>The anti-inflammatory effects of adiponectin are specific to individual multimers, with LMW being most anti-inflammatory </plain></SENT>
<SENT sid="3" pm="."><plain>We postulated that circulating levels of adiponectin and its multimers would be associated with the risk of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>DESIGN: Cross-sectional study </plain></SENT>
<SENT sid="5" pm="."><plain>SETTING: Outpatient clinic in North Carolina, USA </plain></SENT>
<SENT sid="6" pm="."><plain>PATIENTS: Cases of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and controls undergoing upper endoscopy for <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> (GORD) </plain></SENT>
<SENT sid="7" pm="."><plain>MAIN OUTCOME MEASURES: Adjusted odds ratios of plasma adiponectin levels and its multimers for <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: There were 112 cases of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and 199 GORD controls </plain></SENT>
<SENT sid="9" pm="."><plain>Total adiponectin was not associated with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (3(rd) tertile vs 1(st) tertile adjusted odds ratio (aOR) = 0.88; 95% confidence interval (CI) = 0.44 to 1.78) </plain></SENT>
<SENT sid="10" pm="."><plain>High levels of LMW adiponectin were associated with a decreased risk of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (3(rd) tertile vs 1(st) tertile aOR = 0.33; 95% CI, 0.16 to 0.69), and a high LMW/total ratio appeared particularly inversely associated with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (3(rd) tertile vs 1(st) tertile aOR = 0.27; 95% CI, 0.13 to 0.58) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: High levels of LMW adiponectin are associated with a decreased risk of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> among patients with GORD </plain></SENT>
<SENT sid="12" pm="."><plain>Further human studies are required to confirm these findings, and in vitro studies are needed to understand if there is a mechanism whereby adiponectin may affect Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> </plain></SENT>
</text></document>